アブストラクト
| Title | [薬物療法] HFrEF, HFpEF, HFmrEF |
|---|---|
| Subtitle | 特集 予防・治療・緩和ケアの最重要ポイントを押さえる 心不全治療アップデート |
| Authors | 野木一孝, 斎藤能彦 |
| Authors (kana) | |
| Organization | 奈良県立医科大学循環器内科 |
| Journal | 月刊薬事 |
| Volume | 63 |
| Number | 12 |
| Page | 2441-2446 |
| Year/Month | 2021 / 9 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points] ●慢性心不全に対する薬物療法のエビデンスは, 左室駆出率(LVEF)に基づきheart failure with reduced EF(HFrEF), heart failure with preserved EF(HFpEF), heart failure with midrange EF(HFmrEF)の3つに分類される. ●HFrEFでは, アンジオテンシン変換酵素(ACE)阻害薬, アンジオテンシンII受容体拮抗薬(ARB), β遮断薬, ミネラルコルチコイド受容体拮抗薬(MRA)といった生命予後を改善させる薬物療法が確立されており, 最近になりアンジオテンシン受容体ネプリライシン阻害薬(ARNI), SGLT2阻害薬, HCNチャネル遮断薬といった新規薬剤のエビデンスが出てきている. ●HFpEFには, まだ生命予後を改善させる薬剤はなく, 心不全症状の軽減を目的とした負荷軽減療法や, 心不全増悪に結びつく併存症に対する治療を行うことが重要である. ●HFmrEFは, まだ十分に検証されているとはいえないが, 基礎心疾患の分布はHFrEFに近く, 現状ではHFrEFに準じた治療を行うことが推奨される. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study(CONSENSUS). N Engl J Med, 316: 1429-1435, 1987
- 2) SOLVD Investigators; Yusuf S, et al: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med, 327: 685-691, 1992
- 3) SOLVD Investigators; Yusuf S, et al: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 325: 293-302, 1991
- 4) Cohn JN, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med, 325: 303-310, 1991
- 5) Packer M, et al: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation, 100: 2312-2318, 1999
残りの24件を表示する
- 6) Pitt B, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet, 355: 1582-1587, 2000
- 7) Granger CB, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 362: 772-776, 2003
- 8) Pitt B, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 341: 709-717, 1999
- 9) Pitt B, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 348: 1309-1321, 2003
- 10) Zannad F, et al: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 364: 11-21, 2011
- 11) McMurray JJ, et al: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 371: 993-1004, 2014
- 12) Packer M, et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med, 334: 1349-1355, 1996
- 13) The Cardiac Insufficiency Bisoprolol Study II(CIBIS-II): a randomised trial. Lancet, 353: 9-13, 1999
- 14) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure(MERIT-HF). Lancet, 353: 2001-2007, 1999
- 15) Packer M, et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 344: 1651-1658, 2001
- 16) Poole-Wilson PA, et al: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 362: 7-13, 2003
- 17) Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 357: 1385-1390, 2001
- 18) Hori M, et al: Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment(MUCHA) trial. Am Heart J, 147: 324-330, 2004
- 19) Sin DD, et al: The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med, 113: 650-656, 2002
- 20) Bohm M, et al: Heart rate as a risk factor in chronic heart failure(SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 376: 886-894, 2010
- 21) Kotecha D, et al: Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, 384: 2235-2243, 2014
- 22) Nielsen PB, et al: β-Blockers in atrial fibrillation patients with or without heart failure: Association with mortality in a nationwide cohort study. Circ Heart Fail, 9: e002597, 2016
- 23) Cadrin-Tourigny J, et al: Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: An AF-CHF substudy. JACC Heart Fail, 5: 99-106, 2017
- 24) Domanski M, et al: Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction(SOLVD). J Am Coll Cardiol. 42: 705-708, 2003
- 25) Ahmed A, et al: Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J, 27: 1431-1439, 2006
- 26) Masuyama T, et al: Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J, 76: 833-842, 2012
- 27) Gheorghiade M, et al: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA, 297: 1332-1343, 2007
- 28) Konstam MA, et al: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA, 297: 1319-1331, 2007
- 29) Solomon SD, et al: Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med, 381: 1609-1620, 2019
